Contribute Try STAT+ Today

WASHINGTON — Ten House Democrats fired a warning shot in the spring that they could cause trouble for House Speaker Nancy Pelosi’s signature drug pricing reform legislation. But as the House prepares to vote on a multitrillion-dollar spending bill that appears likely to include those drug pricing policies, it’s almost impossible to imagine all 10 voting against the entire package.

STAT asked each of the 10 lawmakers about their most recent stances on drug pricing — some in brief interviews on Capitol Hill, and some via their congressional offices. Already, two lawmakers have actually endorsed the policy. Several others downplayed their objections to it.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment